Navigation Links
Solving the 50-year-old puzzle of thalidomide
Date:11/17/2009

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms of cancer.

Thalidomide was used in over 46 countries following its launch in 1957, but its side effects led to over 10000 children being born with birth defects and the drug was subsequently banned in 1962. However, the drug is now experiencing a renaissance worldwide, particularly across Africa and South America where new cases of thalidomide-induced limb defects are now occurring. This, argues Dr Neil Vargesson of the University of Aberdeen, raises the urgency for research which can target and isolate the drug's negative side effects.

"The mere mention of thalidomide instils fear in some people to this day as it caused the biggest medical disaster in history," said Vargesson. "However it still raises hopes for the treatments of diseases such as Leprosy and multiple myeloma."

Dr Vargesson and his team were the first to demonstrate how the drug causes limb defects by targeting immature blood vessels and now this latest article attempts to link all previous models of thalidomide action together to create one central model. This model proposes that all thalidomide associated defects could be caused by the same 'common mechanism', primarily an effect on angiogenesis, the growth of new blood vessels.

The understanding that the drug's targeting of blood vessels is a 'common mechanism' and the root cause of thalidomide's other side effects raises the possibility of producing a safer form of the drug which can isolate this mechanism and retain clinical benefits.

"Understanding this mechanism resolves a 50-year-old puzzle," concluded Vargesson, "it answers the questions asked by scientists since the first cases were identified in 1958. The possibility of producing analogues of the drug for targeting specific conditions without the devastating side effects is now a very real possibility."


'/>"/>

Contact: Ben Norman
Benorman@wiley.com
44-124-377-0375
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Celiac Disease Provides Clues To Solving Autoimmunity
2. Study finds autistics better at problem-solving
3. MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip
4. Body movements can influence problem solving, researchers report
5. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
6. Study shows potential for resolving type 2 diabetes with bariatric surgery
7. Eating Disorder International Symposium - Shoreline Center for Eating Disorder Treatment and Eating Disorder Awareness Week, Converge on Solving the Life-Threatening Illness
8. Resolving to Break an Addictive Habit?
9. New Strategies for the New Year: Resolving to break an addiction? Help from Harvard Medical School
10. Prevention is the Key to Solving Health Care Crisis;
11. Study further defines potential role of fish-based fatty acids in resolving, preventing asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... As health professionals work to improve their approach to healthcare, ... doing more than filling out a survey; in many cases health professionals and patients ... health care and research on the importance of active engagement with patients and members ...
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
Breaking Medicine Technology: